This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verhelst, J. Articles by Abs, R. Search for Related Content PubMed PubMed Citation Articles by Verhelst, J. Articles by Abs, R. Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Baseline Characteristics and Response to 2 Years of Growth Hormone (GH) Replacement of Hypopituitary Patients with GH Deficiency due to Adult-Onset Craniopharyngioma in Comparison with Patients with Nonfunctioning Pituitary Adenoma: Data from KIMS (Pfizer International Metabolic Database)

General Hospital Middelheim (J.V.), B-2020 Antwerp, Belgium; University of Newcastle (P.K.-T.), Newcastle upon Tyne NE2 4HH, United Kingdom; University Hospital (E.M.E.), S-221 85 Lund, Sweden; Royal Manchester Children’s Hospital (D.A.P.), Manchester M27 4HA, United Kingdom; Saban Research Institute of Childrens Hospital (M.G.), Los Angeles, California 90027; KIGS/KIMS Outcomes Research, Endocrine Care, Pfizer (M.K.-H., P.J.J., P.W.), SE-112 87 Stockholm, Sweden; and University Hospital (R.A.), B-2650 Edegem, Belgium

Address all correspondence and requests for reprints to: Dr. Johan Verhelst, Algemeen Ziekenhuis Middelheim, Department of Endocrinology, Lindendreef 1, 2020 Antwerp, Belgium. E-mail: johan.verhelst{at}zna.be.

Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement.

Patients: Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients.

Results: At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m²; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy.

Conclusions: In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time.

This article has been cited by other articles:

				H. Holmer, B. Ekman, J. Bjork, C.-H. Nordstom, V. Popovic, A. Siversson, and E.-M. Erfurth Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy Eur. J. Endocrinol., November 1, 2009; 161(5): 671 - 679. [Abstract] [Full Text] [PDF]

				G Brabant, E M Poll, P Jonsson, D Polydorou, and I Kreitschmann-Andermahr Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations? Eur. J. Endocrinol., November 1, 2009; 161(S1): S25 - S31. [Abstract] [Full Text] [PDF]

				J. D J Thomas and J. P Monson Adult GH deficiency throughout lifetime Eur. J. Endocrinol., November 1, 2009; 161(S1): S97 - S106. [Abstract] [Full Text] [PDF]

				M. Koltowska-Haggstrom, A. F Mattsson, and S. M Shalet Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations Eur. J. Endocrinol., November 1, 2009; 161(S1): S51 - S64. [Abstract] [Full Text] [PDF]

				J. Verhelst and R. Abs Cardiovascular risk factors in hypopituitary GH-deficient adults Eur. J. Endocrinol., November 1, 2009; 161(S1): S41 - S49. [Abstract] [Full Text] [PDF]

				D Maiter, R Abs, G Johannsson, M Scanlon, P J Jonsson, P Wilton, and M Koltowska-Haggstrom Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur. J. Endocrinol., August 1, 2006; 155(2): 253 - 260. [Abstract] [Full Text] [PDF]

				M. Koltowska-Haggstrom, A. F Mattsson, J. P Monson, P. Kind, X. Badia, F. F Casanueva, J. Busschbach, H. P F Koppeschaar, and G. Johannsson Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur. J. Endocrinol., July 1, 2006; 155(1): 109 - 119. [Abstract] [Full Text] [PDF]